M. Hartmann

The ESMO magnitude of clinical benefit scaling tool: from theory to practice.

M. Hartmann, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Real-world data in drug development strategies for orphan drugs: tafasitamab in B cell lymphoma, a case study for approval based on a single-arm combination trial.

M. Hartmann, T. Ligensa, P. Serrano, 2022, Drug discovery today.

Concepts for the Risk-Based Regulation of Clinical Research on Medicines and Medical Devices

M. Hartmann, F. Hartmann-Vareilles, 2012 .

Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective

M. Hartmann, P. Serrano, J. Gross, 2018, Clinical pharmacology and therapeutics.

Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries

M. Hartmann, 2012, Trials.

The Clinical Trials Directive: How Is It Affecting Europe's Noncommercial Research?

M. Hartmann, F. Hartmann-Vareilles, 2006, PLoS clinical trials.

Legal Requirements, Definitions, and Standards for Non-interventional Drug Studies: A Global Picture of Variability—Results and Conclusions From a Single-Institution Survey

M. Hartmann, Patricia Schaffner, 2013, Therapeutic innovation & regulatory science.

Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.

M. Hartmann, Christine Mayer-Nicolai, O. Pfaff, 2013, Critical reviews in oncology/hematology.